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Currently, more than 600,000 immi-
grants enter the United States each year from coun-
tries where intestinal parasites are endemic. At entry
persons with parasitic infections may be asympto-
matic, and stool examinations are not a sensitive
method of screening for parasitosis. Albendazole is
a new, broad-spectrum antiparasitic drug, which
was approved recently by the Food and Drug Admin-
istration. International trials have shown albendazole
to be safe and effective in eradicating many para-
sites. In the United States there is now disagreement
about whether to screen all immigrants for parasites,
treat all immigrants presumptively, or do nothing




We compared the costs and benefits of
no preventive intervention (watchful waiting) with
those of universal screening or presumptive treat-
ment with 400 mg of albendazole per day for five
days. Those at risk were defined as immigrants to
the United States from Asia, the Middle East, sub-
Saharan Africa, Eastern Europe, and Latin America
and the Caribbean. Cost effectiveness was expressed
both in terms of the cost of treatment per disability-
adjusted life-year (DALY) averted (one DALY is de-
fined as the loss of one year of healthy life to dis-





As compared with watchful waiting, pre-
sumptive treatment of all immigrants at risk for par-
asitosis would avert at least 870 DALYs, prevent at
least 33 deaths and 374 hospitalizations, and save at
least $4.2 million per year. As compared with watch-





Presumptive administration of alben-
dazole to all immigrants at risk for parasitosis would
save lives and money. Universal screening, with treat-
ment of persons with positive stool examinations,
would save lives but is less cost effective than pre-
sumptive treatment. (N Engl J Med 1999;340:773-9.)
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MMIGRATION to the United States has
reached a historic high, with nearly 1 million





600,000 came from countries where intestinal
parasites are endemic. Health policy with respect to
managing parasitic disease varies within the United
States and internationally. Governmental recommen-
dations include universal screening, selective screen-




 Economic analyses of




Presumptive treatment became a viable option in
mid-1997, when the Food and Drug Administration





 This drug is inexpensive and is effective
against 
 










us), Strongyloides stercoralis, Giardia lamblia, Opisthor-








Albendazole has been administered presumptively to
thousands of persons living in areas of endemic dis-
ease and has caused no side effects requiring medical




 Its safety has not been
tested extensively in children under two years of age
or in pregnant women.
Given the safety, efficacy, and low cost of albenda-
zole, presumptive treatment of all immigrants to the
United States has intuitive appeal. Nonetheless, be-
cause thousands of immigrants would have to be
treated to prevent a few serious adverse events, a for-
mal cost-effectiveness analysis is needed to guide
public health policy. We undertook such an analysis.
The data base of the Healthcare Cost and Utiliza-
tion Project 3 (HCUP-3) contains information on





 These data, howev-
er, do not permit geographic areas with large num-
bers of immigrants to be separated from those with
I
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few immigrants. Moreover, cases of parasitosis ac-
quired in areas of the United States where parasites
are endemic are included in the data base. The data
base of the New York Statewide Planning and Re-





formation that allows the probability of hospitaliza-
tion for parasitic disease to be calculated for a
nonendemic area with a large proportion of immi-
grants. Outpatient morbidity can be estimated on
the basis of Medicaid reports from the Claim De-
tail/Special Reports (CD/SR) System of the New





 We used data from these sources
as the basis of our analyses.
In this report, outcomes are expressed in terms of
disability-adjusted life-years (DALYs) averted. One
DALY equals the loss of one healthy year of life to
disease. One DALY averted is approximately equal to












Costs and outcomes were considered over the lifetime of the
cohort, from the perspective of society as a whole. All future costs





 was used, and costs associated with secondary
transmission and lost productivity were included. Our chief as-
sumptions are listed in Table 1. The models did not take into ac-
count the presence or absence of symptoms, because symptoms




The term “immigrants” in this study refers to documented and
undocumented foreign entrants who plan to reside permanently





 Immigrants at risk for parasitosis were defined as im-
migrants from one of the following five regions: Eastern Europe,
Latin America and the Caribbean, sub-Saharan Africa, the Mid-




A decision-analysis model was constructed with the use of
DATA 3.0 software for the Macintosh computer (TreeAge Soft-
ware, Williamstown, Mass.). The model examined three strategies:
universal screening (with treatment of infected persons only), uni-
versal treatment, and no preventive intervention (watchful wait-
ing). The variables used in the model are presented in Table 2.









 We excluded 
 
Schisto-







data predicted that the number of hospitalizations due to infec-













were excluded from the analysis because these organisms can be
acquired in New York State, a fact that makes it difficult to deter-
mine whether the infection causing hospitalization was acquired
domestically or abroad. Because 
 







 are susceptible to albendazole, their exclusion
caused the model to underestimate the benefits of presumptive
treatment.
Each variable was tested for its influence on the results of the
model in univariate and bivariate sensitivity analyses. The most
plausible value for each variable was used to create a base-case re-
sult (Table 2). A best-case scenario was generated by assigning
each variable the most extreme plausible value that would make
presumptive treatment more cost effective. A worst-case scenario
was created in a similar fashion.
 
Sensitivity of the Stool Test and Prevalence of Parasites
 
The sensitivity of the stool examination for ova and parasites




 The prevalence of each para-
site in the immigrant population was calculated from the known
sensitivity of a single stool examination and the published rate of






Data on hospitalizations were obtained from the New York




 The number of pre-
ventable future hospitalizations per year was estimated on the ba-
sis of the mean number of hospitalizations per year from 1990
through 1996. The New York City data were used because one
third of the city’s residents are immigrants, and because none of
the parasites under study are endemic in the city.
The number of outpatient visits to health care providers was
calculated on the basis of reports or Medicaid claims from the
CD/SR System of the New York State Department of Health’s




 The number of preventable fu-
ture outpatient visits per year was estimated on the basis of the
mean number of outpatient visits per year from 1992 through
1996. Because the CD/SR System contains only data on Medicaid
recipients, these data were adjusted to reflect all at-risk immigrants


























































Every case of parasitosis in the data base of the New York Statewide Plan-
ning and Research Cooperative System occurred in an immigrant.
None of the parasites in question is endemic in New York City.










Cases of parasitosis in war veterans and institutionalized persons were 
excluded from the analysis.
The entire cost of hospitalization for patients with a primary diagnosis of 
strongyloidiasis was attributable to strongyloidiasis.





 infection was recorded as the primary diagnosis. We assumed 










 infection as a nonprimary diagnosis.




No deaths due to infections with these organisms were recorded in the 














with the prescribed regimen is 100 percent effective.
Studies show that 85 to 100 percent of organisms are eliminated with a 






Even a partial reduction in the burden of parasites greatly reduces the 









 infection with the prescribed regimen is 85 
percent effective.






A partial reduction in the burden of parasites may not reduce the chance 




 can reproduce in the 
host.
Compliance among immigrants is similar to compliance in the field trials 
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patient visits in terms of present value, it was necessary to estimate
the discounted probability of illness. This was defined as follows:
where P is the lifetime probability of illness due to a given para-
site, N is the mean annual number of hospitalizations or outpa-




 t is the life expectancy of the
parasite in years, I is the total number of infected immigrants re-




 and r is the discount rate.




 resolves in a popula-




 In the calculation




 the value of I in-
cluded all New York City immigrants infected with parasites, re-




 This definition would
result in an underestimate of P if the prevalence of parasitic infec-
tion decreased over time.









immigrants, we assumed that the same proportion of New York
City immigrants would have these illnesses as of immigrants to the
rest of the United States. This assumption was validated by a
comparison of the predicted number of hospitalizations nation-














 and hookworm infections was equiva-








 infection, the model predicted 91.6 percent




 Some of the difference may be
accounted for by locally acquired parasitic infections reflected in the










infection, according to the HCUP-3 data, was 16.7 per-
cent. There were not enough cases listed in this data base for us
to estimate mortality from any other parasite. De Silva et al. esti-
 





 infections were assumed to cause no deaths. HCUP-3 denotes Healthcare Cost and




































































































 Low values are set 















































 infection 22 — Age at onset of disease was obtained from HCUP-3.15
Probability of medical
care and outcomes
Outpatient visit 0.0098 0.0041–0.0098 The probability of an outpatient visit for 
Strong. stercoralis.17,21,29
Hospitalization 0.00197 0.0009–0.0048 The probability of admission for Strong. stercoralis 
infection.16,21,29
Side effects 0.01 0–0.05 The assumed probability of a post-treatment medical 
visit.









The probability that the patient will die of disseminated 
strongyloidiasis.15
The probability that the patient will die of 
A. lumbricoides infection.30 
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mated mortality from A. lumbricoides infection to be approxi-
mately 5 percent among those hospitalized, on the basis of a
weighted mean of case fatality rates in the international litera-
ture.30 One country for which data were used in devising this
weighted mean, Brazil, had a mortality rate twice as high as the
mean for the group of countries; it was considered an outlier and
removed from the present analysis. This exclusion reduced the
weighted mean mortality rate to 3.6 percent.
Costs
The wholesale costs of albendazole were obtained from Medi-
Span, a data base of wholesale drug costs.26 It was assumed that
the cost of distribution of the medication would be $0.25 per pa-
tient, resulting in a total cost of $8.81 per patient for a regimen
of 400 mg per day for five days. Although albendazole caused no
side effects requiring medical attention in field trials,8-14 it was as-
sumed that 1 percent of all treated immigrants would require a
follow-up visit.
The costs of lost productivity for all immigrant groups were es-
timated on the basis of data from the Office of Refugee Resettle-
ment.27 The average length of the hospital stay for the treatment
of each type of parasite was used to estimate lost wages due to
hospitalization.15 It was assumed that patients would require two
working days for recovery after hospitalization and would lose
two hours’ worth of wages as a result of outpatient visits. 
Mean hospital charges were derived from the HCUP-3 data.
Medicaid reimbursement rates were used to estimate outpatient
costs associated with parasitic illness and with medical visits for
the evaluation of patients with positive stool samples and side ef-
fects of medication.15,28 All costs were converted to 1997 dollars
with use of the medical portion of the Consumer Price Index.
DALYs
DALYs averted were calculated according to the methods and
disability weights cited in Murray and Lopez,43 with use of the
Mathematica software package (Wolfram Research, Oxfordshire,
United Kingdom). So as to ensure comparability with other
North American cost-effectiveness studies, DALYs were not
weighted for age.
RESULTS
Costs Associated with Preventive Intervention
The model predicted that at least 33 deaths, 374
hospitalizations, and $4.2 million in costs would be
averted annually if all 1996 immigrants from the five
regions received presumptive treatment rather than
no preventive intervention (Table 3). When applied
separately to each of the regions considered, the
model predicted that presumptive treatment would
save costs for immigrants from all regions but the
Middle East, where the incremental cost would equal
$4,630 per DALY averted or $5,029 per hospitaliza-
tion averted. The model predicted that screening
would avert fewer DALYs than presumptive treat-
*DALY denotes disability-adjusted life-year. Because all figures have been rounded to the nearest whole number, it may
not be possible to reproduce exact calculations. Costs and DALYs have been discounted at 3 percent.
†A negative number indicates a cost savings.
‡Cost savings were realized for all regions except the Middle East. No values are shown for other regions, because cost-
effectiveness ratios cannot be calculated for cost-saving interventions.
§Costs shown are the amounts by which the costs with screening exceed those with presumptive treatment.
TABLE 3. COST EFFECTIVENESS OF PRESUMPTIVE TREATMENT AND SELECTIVE SCREENING, 
AS COMPARED WITH NO PREVENTIVE INTERVENTION.*












No. of immigrants in 1996 282,632 5,047 51,537 267,334 91,972 698,522
No preventive intervention
Gross cost ($) 6,330,957 40,073 1,154,429 2,649,280 911,443 11,086,181
Hospitalizations (no.) 228 1 33 94 18 374
Treatment with albendazole
Gross cost ($) 3,227,657 46,634 588,553 2,550,366 877,413 7,290,624
Net cost ($)† ¡3,103,299 6,561 ¡565,876 ¡548,035 ¡34,030 ¡4,244,679
Lives saved (no.) 21 0 4 7 2 33
DALYs averted (no.) 543 1 94 191 40 870
Cost/DALY averted ($)‡ — 4,630 — — — —
Cost/hospitalization 
averted ($)‡
— 5,029 — — — —
Screening
Gross cost ($) 18,077,143 256,741 3,296,307 14,075,135 4,842,326 40,547,651
Net cost ($) 11,746,186 216,668 2,141,878 11,425,855 3,930,883 29,461,470
Incremental cost ($)§ 14,849,485 210,107 2,707,754 11,973,890 3,964,913 33,706,149
Lives saved (no.) 7 0 1 3 1 12
DALYs averted (no.) 115 0 20 41 9 185
Cost/DALY averted ($) 101,801 722,372 106,706 280,966 457,383 159,236
Cost/hospitalization 
averted ($)
56,491 169,981 73,597 131,011 229,915 85,989
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ment in all regions; it also predicted that screening
would cost $159,236 per DALY averted and $85,989
per hospitalization averted, as compared with watch-
ful waiting.
Sensitivity Analyses
The outcome of each strategy was most sensitive
to changes in the following variables, in descending
order of sensitivity: the prevalence of Strong. ster-
coralis infection, the probability that treatment will
be successful, the probability that the medication
produces side effects, the probability of hospitaliza-
tion due to Strong. stercoralis, and the cost of hospi-
talization.
In a bivariate sensitivity analysis, the mean preva-
lence of Strong. stercoralis was varied between zero
and the highest values obtained from the medical lit-
erature (Fig. 1). The threshold value for cost savings
was tested for each variable to which the model was
sensitive (Table 4). The outcome was qualitatively
unchanged (i.e., presumptive treatment resulted in
cost savings as compared with watchful waiting) for
all plausible values used for all variables tested. Pre-
sumptive treatment also saved money when we used
discount rates ranging from 0 percent (1439 DALYs
averted and $8.6 million saved) to 5 percent (32
DALYs averted and $2.7 million saved).
In the best-case scenario, presumptive treatment
would save $16.4 million while preventing 1976
DALYs and averting 700 hospitalizations, as com-
pared with watchful waiting. In the worst-case sce-
nario, presumptive treatment would cost $25,644
per DALY averted and $16,481 per hospitalization
averted, also as compared with watchful waiting.
DISCUSSION
If all immigrants to the United States in 1996
who were at risk for intestinal parasitosis had been
given a five-day course of albendazole (400 mg
orally per day), 33 lives would have been saved, 374
Figure 1. Two-Way Sensitivity Analysis.
The intersection of the prevalence of Strongyloides stercoralis infection with the sum of the prevalence
rates for Ascaris lumbricoides, hookworm, and Trichuris trichiura infections indicates whether pre-
sumptive treatment costs more than watchful waiting (solid area) or saves money (open area). Means












































































29 Cost savings would be realized so long 
as the efficacy of treatment was 
greater than 29 percent.
Side effects 20 Cost savings would be realized so long 
as albendazole produced side effects 
requiring a follow-up visit in fewer 





34 Cost savings would be realized so long 
as the actual probability of hospital-
ization for Strong. stercoralis infec-
tion was not less than 34 percent of 
the predicted value.
Real value of charges 69 Cost savings would be realized overall 
so long as society’s actual costs were 
not lower than 69 percent of the 
charges reported by hospitals.
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hospitalizations would have been averted, and 870
DALYs would have been averted. Holding preva-
lence constant, the best-case scenario predicted a
cost savings of $16.4 million and prevention of 1976
DALYs, and the worst-case scenario predicted a cost
of $25,644 per DALY averted.
Outcomes differed among the regions of origin of
immigrants according to the prevalence of parasites.
For an immigrant group with a known prevalence,
Figure 1 can be used to determine whether or not
presumptive treatment would save costs.
The exclusion of parasites susceptible to albenda-
zole and the use of conservative assumptions about
the probability of illness due to Strong. stercoralis de-
creased the predicted cost savings associated with
the substitution of presumptive treatment for watch-
ful waiting. Despite the fact that the model was con-
servative with respect to the benefits of presumptive
treatment, savings were still predicted. This increases
the likelihood that cost savings would result if per-
fect data were available.
The decision-analysis model was robust when
changes were made in all variables over the range of
their plausible values, and cost savings with pre-
sumptive treatment persisted in all univariate sensi-
tivity analyses. Even in the worst-case scenario, the
cost-effectiveness ratio for presumptive treatment of
parasites compares favorably with that for the pre-
vention of opportunistic infections in patients with
the acquired immunodeficiency syndrome.44 The
mathematical model used to calculate morbidity due
to parasites underestimated the total number of cas-
es recorded in the HCUP-3 data base. Because some
of the hospitals included in this data base were lo-
cated in areas where the parasites we studied were
endemic, it is likely that the model predicts the prev-
alence of illness in immigrant populations more ac-
curately than would the HCUP-3 data base.
Strong. stercoralis infection was responsible for most
of the deaths and hospital costs in this study. This
organism typically causes severe illness in patients re-
ceiving immunosuppressive therapy.45 We assumed
that the costs of hospitalization for the underlying
illnesses leading to immunosuppressive therapy would
not have been incurred had the patient been unin-
fected; however, clinical strongyloidiasis may have
developed in some patients during prolonged hospi-
tal stays for other illnesses. The effect of this assump-
tion on costs is offset by the conservative assump-
tions used to determine the probability of illness due
to the organism. Furthermore, only patients with a
primary diagnosis of strongyloidiasis were included
in the analysis.
Mortality due to Strong. stercoralis infection al-
most invariably results from the hyperinfection syn-
drome, which is fatal in 61 percent of cases in hos-
pitalized persons.45 Among uninfected patients with
conditions that commonly predispose patients to the
hyperinfection syndrome, less than 0.1 percent of
those in the SPARCS data base died while in the
hospital, whereas 16.7 percent of hospitalized pa-
tients with a primary diagnosis of massive strongy-
loidiasis died.16,45
Another limitation of the study is that E. histolyt-
ica was not included in the decision-analysis model
because it is present in untreated water sources in
New York State. Inclusion of this parasite might have
decreased the marginal cost of screening as com-
pared with watchful waiting, but it would have had
no effect on the cost of treatment as compared with
watchful waiting. Finally, the true savings to society
may have been underrepresented because it was nec-
essary to exclude Taen. solium, G. lamblia, O. viver-
rini, and H. nana infections, which are susceptible
to albendazole therapy.
In rare instances, O. viverrini causes cholangiocar-
cinoma, a fatal cancer that may be prevented by the
treatment regimen we studied in infected persons
who have not yet undergone malignant changes.11,46
Neurocysticercosis is the most common inpatient
disorder due to parasitic infection.15 Public health
benefits may be realized from eradicating Taen. soli-
um by means of mass treatment.47,48 There is a hypo-
thetical risk of seizure or blindness associated with
the treatment of occult neurocysticercosis, but no
side effects requiring medical attention have occurred
in thousands of patients in areas where the disease is
endemic who have received albendazole at doses
similar to those used in this study.8-14 Clinicians may
wish to inquire about the presence of headaches or
seizures before initiating presumptive treatment, and
they should not consider treatment a substitute for
other preventive or diagnostic tests, such as liver-
enzyme studies.
The cost of albendazole treatment in this analysis
was $8.56 (exclusive of the distribution charge), be-
cause this was the prevailing wholesale price in the
United States in 1997, but government purchasers in
the United States would pay less. This regimen can
be purchased for as little as $0.71 in other countries.
Ivermectin, an alternative drug for presumptive
treatment that is more effective against Strong. ster-
coralis than albendazole, was not analyzed because
of its high cost ($19.30)26 and its narrow spectrum
of coverage.12
Cost savings resulting from medical interventions
are rare. Precedents for such cost savings include tar-
geted vaccination and contraceptive use by adoles-
cents.49,50 Though the treatment strategy we studied
did not reduce medical costs for immigrants from
the Middle East — because of the low prevalence of
parasites in that population — the cost per DALY
averted was similar to the costs associated with
smoking cessation according to guidelines of the
Agency for Health Care Policy and Research.51 The
costs per DALY averted for screening of Asian and
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sub-Saharan African immigrants were similar to those
associated with vaccination against hepatitis A in
health care workers.52
We are indebted to Marcelle Layton, M.D., Susan Cookson, M.D.,
and Martin Cetron, M.D., for their help with the design of the cost-
effectiveness analysis and with editing of the manuscript and to Burt
Roberts, M.P.A., for assistance with the preparation of the manu-
script.
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